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DObjective: Patients undergoing cardiac surgery with a history of untreated atrial fibrillation have reduced sur-
vival compared with similar patients without atrial fibrillation. We sought to compare the midterm survival of
patients who received concomitant surgical ablation treatment for atrial fibrillation (atrial fibrillation ablated)
with that of matched patients without a history of atrial fibrillation (no atrial fibrillation).
Methods:We evaluated 3262 consecutive patients (813 [25%] with atrial fibrillation and 2449 [75%] without
preoperative atrial fibrillation) undergoing cardiac surgery at a single institution from April 2004 to April 2009.
Of patients with atrial fibrillation, 565 (70%) were treated with a concomitant surgical ablation procedure. Pro-
pensity scores were calculated on the basis of 37 known preoperative risk factors and yielded 744 patients. Mid-
term survival was compared between patients with atrial fibrillation ablation (n ¼ 372) and patients without
atrial fibrillation (n ¼ 372). Survival was also compared between patients with successful vs unsuccessful ab-
lation, and a matched analysis was performed at 1 year between the 2 groups.
Results:Mean follow-up was 2.7  1.6 years. Patients without atrial fibrillation and patients with treated atrial
fibrillation had similar early 30-day mortality (1.2% vs 0.3%, P ¼ .37) and overall mortality rates (11.6% vs
9.4%, P¼ .344), respectively. Survival analysis showed no differences at 1, 3, and 5 years between the 2 groups
(log-rank P ¼ .22). At last follow-up, 78% of treated patients were free of atrial fibrillation. At 1 year, 68% of
patients were free of atrial fibrillation and antiarrhythmic medication. Freedom from atrial fibrillation and an-
tiarrhythmic medication at 1 year predicted improved midterm survival (P ¼ .03) compared with patients in
atrial fibrillation or taking antiarrhythmic medication. Propensity-matched analysis after 1 year demonstrated
improved survival for patients who were successfully treated (P ¼ .016).
Conclusions: Patients undergoing surgical treatment of atrial fibrillation had survival similar to that of patients
without a history of atrial fibrillation. Those with successful sinus restoration had improved survival compared
with those who were treated but remained in atrial fibrillation. (J Thorac Cardiovasc Surg 2012;143:1341-51)Earn CME credits at
http://cme.ctsnetjournals.org
Patients with atrial fibrillation (AF) have a reduced survival
when compared with patients in sinus rhythm.1 Patients
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The Journal of Thoracic and Carall-cause mortality.2 Pharmacologic attempts at sinus resto-
ration have been unable to establish a survival advantage
over rate control alone.3 However, on subsequent multivar-
iate analysis, patients with successful restoration of sinus
rhythm demonstrated a survival advantage over those in
AF, suggesting that a therapy that successfully treats AF
may affect survival.4
Patients with preoperative AF undergoing cardiac
surgery also have an increased risk of mortality.5-9 For
example, patients with AF undergoing coronary artery
bypass grafting (CABG) have a 24% survival
disadvantage at 10 years compared with matched patients
undergoing CABG without preoperative AF.5,6 In
matched patients undergoing aortic valve replacement,
patients with AF have worse survival and an increased
incidence of strokes and heart failure.7,8
Surgical ablation of AF in patients undergoing cardiac
surgery has improved and is more widely applied, but it is
still performed in the minority of cases.10 Ablation usually
adds little to the operation (9 minutes to crossclamp time
and 9 minutes to cardiopulmonary bypass time in patientsdiovascular Surgery c Volume 143, Number 6 1341
Abbreviations and Acronyms
AA ¼ antiarrhythmic
AF ¼ atrial fibrillation
CABG ¼ coronary artery bypass grafting
CI ¼ confidence interval
HR ¼ hazard ratio
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Dundergoing mitral valve surgery).10 Surgery for AF has
been shown to be safe and effective and does not add to peri-
operative morbidity and mortality when combined with
other cardiac procedures; however, a benefit to midterm sur-
vival has not been established.11-15
The purpose of this study was to compare the midterm
survival of patients with AF who received surgical ablation
for AF (AF ablated) at the time of cardiac surgery with that
of similar patients without preoperative AF (no AF). Our
hypotheses were that (1) the AF ablated group would
have a similar survival as the no AF group after adjusting
for preoperative risk factors, and that (2) the successful res-
toration of sinus rhythm would improve survival compared
with patients who return to AF.MATERIALS AND METHODS
We queried the Bluhm Cardiovascular Institute’s Clinical Trials Cardiac
Surgery Outcomes Registry for all patients who underwent cardiac surgery
since the inception of the database fromApril 2004 to April 2009. This Reg-
istry is approvedby the institutional reviewboard atNorthwesternUniversity
(project STU00012288). Data were collected from patients enrolled in the
Registry and frommedical record review.All patients in this study consented
for the use of their follow-up data. Data were deidentified before analysis.Study Population
We evaluated 3262 consecutive patients (813 [25%] with AF and 2449
[75%] without preoperative AF). Of the 813 patients with AF, 565 (70%)
were treated with a surgical AF ablation procedure (classic cut-and-sew
Maze in 78, biatrial Maze in 140, left atrial Maze in 213, pulmonary
vein isolation [island] in 108, pulmonary vein isolation [box] in 23, and
procedures that not fit into any other category in 3). The AF untreated
(n ¼ 248) group had similar age but several adverse preoperative risk fac-
tors, including diabetes, hypertension, congestive heart failure, New York
Heart Association class, renal failure, chronic obstructive pulmonary dis-
ease, peripheral vascular disease, myocardial infarction, stroke, and tran-
sient ischemic attack compared with the AF ablated group (Table 1).
Patients were treated for AF when the risks of adding the procedure were
considered to be low, there was a reasonable chance for success, and the
surgery was performed by an experienced surgeon in accordance with
the Heart Rhythm Society/European Heart Rhythm Association/European
Cardiac Arrhythmia Society Expert Consensus Statement.16 Preoperative
demographic and clinical data were collected on all patients, as were peri-
operative outcomes. The standard Society of Thoracic Surgeons’ database
definitions were used for all variables. The Society of Thoracic Surgeons’
risk score could not be implemented in those with AF; therefore, Ambler
risk scores were calculated and compared. Midterm survival was identified
by the Social Security Death Index and measured as time (days) to death or
last follow-up from date of surgery. Follow-up was 100% complete.1342 The Journal of Thoracic and Cardiovascular SurStatistical Analysis
Before final statistical analysis, preliminary data were analyzed using
univariate and graphic methods wherever applicable to facilitate inspection
and interpretation of the data. Outliers and influential observations were
identified and checked for accuracy. Data error due to data entry oversight
was appropriately corrected. Data were summarized using descriptive sta-
tistics (eg, means and standard deviation for continuous variables; count
and frequency for categoric variables). Group differences in patient demo-
graphics and clinical and surgical characteristics were compared using
a t test (parametric) or Wilcoxon Mann–Whitney test (nonparametric) for
continuous variables and chi-square test or Fisher exact test for categoric
data.
Unadjusted survival estimates were analyzed using the Kaplan–Meier
method, and adjusted hazard ratio (HR) of long-term mortality was esti-
mated using the Cox proportional hazard models. Risk factors by which
these survival estimates were adjusted for are shown in Table 2. Propensity
scores were further calculated on the basis of the probability of undergoing
a surgical AF ablation procedure and no preoperative AF condition. The
propensity score was developed by fitting a logistic regression model
with AF treatment as the outcome variable and all risk factors in Table 1
as the predictor variables. Missing data of predictor variables were imputed
using multiple imputations of SAS PROCMI (SAS Institute Inc, Cary, NC)
procedure. All P values after propensity score adjustment were not statis-
tically significant (Table 2), indicating a good balance after adjustment.
The AF ablated group (n¼ 372) was propensity matched (1:1) with the
no AF history (n ¼ 372) group using the caliper-matching method.17 Spe-
cifically, we imposed a 0.02 propensity score tolerance on the maximum
propensity score distance (caliper) in our matching algorithm so that bad
matches could be avoided. Balance of covariates before and after propen-
sity adjustment was checked using both density distribution of the propen-
sity score and Wald chi-square statistics to access the quality of the match.
The 744 matched patients were analyzed for differences in midterm sur-
vival using Kaplan–Meier and log-rank methodology. Additional matches
were performed for patients undergoing isolated aortic valve replacement
(n ¼ 44), mitral valve repair or replacement (n ¼ 130), and concomitant
coronary artery bypass and valve intervention (CABGþvalve) (n ¼ 186).
For the AF ablated group, the standard protocol for postoperative mon-
itoring and medication management of AF at Bluhm Cardiovascular Insti-
tute, developed in collaboration with cardiac electrophysiologists, was
reviewed with patients and shared with referring cardiologists. The proto-
col recommends continuous electrocardiographic monitoring for a mini-
mum of 24 hours at 3 and 6 months to guide medication changes and
every 6 months for 2 years after intervention to monitor rhythm status.
Pacemaker interrogation was used whenever possible. If any monitor
showed AF and no further attempts were made to restore sinus rhythm,
the patient was deemed a ‘‘failure’’ and continuous monitoring was no lon-
ger required. Patients were also contacted by phone at 3, 6, and 12 months
to track medications and provide support.
Survival was compared in the AF ablation group between patients with
successful sinus restoration and patients with ‘‘failed’’ treatment. Success
was defined at 1 year as freedom from of any episode of AF without anti-
arrhythmic (AA) medications. Throughout the report, statistical signifi-
cance was established at an alpha level of .05. All statistical analyses
were performed using SAS 9.2 statistical software (SAS Institute Inc). In
an effort to assess whether the return to AF was a marker or cause of mor-
tality, after 1 year, 77 patients successfully treatedwere propensitymatched
(1:1) with 77 patients with unsuccessful treatment using the caliper match-
ing method.17,18We again imposed a 0.02 propensity score tolerance on the
maximum propensity score distance (caliper) in our matching algorithm so
that bad matches could be avoided. Covariate balance before and after
propensity adjustment was checked using both density distribution of the
propensity score and Wald chi-square statistics to access the quality of
the match. The 154 matched patients were analyzed for differences in mid-
term survival using Kaplan–Meier and log-rank methodology.gery c June 2012
TABLE 1. Comparison of characteristics in the AF population: AF ablated versus AF untreated
Variables
AF ablated (N ¼ 565) AF untreated (N ¼ 248)
P valuen % n %
Demographics
Age (mean  SD) 65.9  12.2 66.5  15.1 .5628
Male 329 58.2 173 69.8 .0018
Race .0376
White 435 77.0 194 78.2
AA 26 4.6 20 8.1
Hispanic 10 1.8 7 2.8
Asian 11 2.0 5 2.0
Other 83 14.7 22 8.9
Health characteristics
CHADS2 (mean  SD) 1.6  1.2 2.3  1.3 <.0001
BMI (mean  SD) 27.5  5.9 27.7  6.5 .7728
Smoker 149 26.4 68 27.4 .7559
Diabetes 77 13.6 66 26.6 <.0001
Hypertension 321 56.8 164 66.1 .0127
CHF 206 36.5 149 60.1 <.0001
NYHA <.0001
Class 1 121 21.4 19 7.7
Class 2 246 43.5 65 26.2
Class 3 173 30.6 91 36.7
Class 4 25 4.4 73 29.4
Renal failure 24 4.2 30 12.1 <.0001
Previous dialysis 5 0.9 11 4.4 .0008
COPD 71 12.6 58 23.4 .0001
PVD 26 4.6 29 11.7 .0002
Moderate pulmonary HTN 188 33.3 79 31.9 .6915
Severe pulmonary HTN 130 23.0 67 27.0 .2195
MI 58 10.3 69 27.8 <.0001
Angina 70 12.4 43 17.3 .0603
Stroke/TIA 57 10.1 46 18.5 .0008
Family history CAD 105 18.6 38 15.3 .2607
Surgical characteristics
No. of diseased vessels (mean  SD) 0.8  1.2 1.3  1.3 <.0001
Left main disease 30 5.4 32 13.2 .0001
Preoperative creatinine (mean  SD) 1.17  0.8 1.46  1.1 .0002
Surgical incidence <.0001
1st 465 82.3 137 55.2
2nd 90 15.9 93 37.5
3þ 10 1.8 18 7.3
Indication of surgery <.0001
Elective 511 90.4 138 55.7
Emergency 1 0.2 10 4.0
Urgent 53 9.4 100 40.3
Type of surgery
CABG 172 30.4 83 33.5 .3920
Aortic valve 167 29.6 107 43.1 .0002
Mitral valve 341 60.4 51 20.6 <.0001
Tricuspid valve 162 28.7 42 16.9 .0004
ValveþCABG 141 25.0 50 20.2 .1376
Previous medications
ACE 201 35.7 87 35.2 .8957
ADP 9 1.6 12 4.9 .0071
Aspirin 121 21.4 96 38.9 <.0001
Beta-blockers 362 64.1 138 55.6 .0230
(Continued)
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AF ablated (N ¼ 565) AF untreated (N ¼ 248)
P valuen % n %
Warfarin 88 15.6 69 28.0 <.0001
Nonstatin 28 5.0 17 6.9 .2756
Statin 240 42.5 120 48.4 .1183
Discharge medications
ACE 129 23.7 50 23.0 .8535
ADP 17 3.1 18 8.0 .0026
Aspirin 500 90.1 206 91.6 .5269
Beta-blockers 381 70.0 151 67.1 .4241
Warfarin 472 85.2 121 53.5 <.0001
Nonstatin 23 4.1 13 5.2 .4548
Statin 406 71.9 160 64.5 .03613
Ambler score (mean  SD) 8.4  8.2 12.5  9.8 <.0001
AF, Atrial fibrillation; SD, standard deviation; AA, antiarrhythmic; CHADS2, Congestive heart failure, Hypertension, Age 75 years, Diabetes, previous Stroke; BMI, body mass
index; CHF, congestive heart failure; NYHA,NewYork Heart Association; COPD, chronic obstructive pulmonary disease; PVD, peripheral vascular disease;HTN, hypertension;
MI, myocardial infarction; TIA, transient ischemic attack; CAD, coronary artery disease; CABG, coronary artery bypass grafting; ACE, angiotensin-converting enzyme; ADP,
adenosine diphosphate.




There was no difference in 30-day mortality (0.3% vs
1.2%, P ¼ .4) (Ambler score predicted mortality 6.9%
and 6.3%, P ¼ .22), postoperative stroke (2.4% vs 4.1%,
P ¼ .15), length of stay (8 vs 9 days, P ¼ .3), intensive
care unit stay (77 vs 80 hours, P ¼ .8), or length of
follow-up (2.8 vs 2.7 years, P ¼ .12) between the
propensity-matched AF ablated and no AF groups,
respectively.
In the unadjusted model, patients undergoing surgery
with a history of AF had reduced survival compared with
patients with no AF (Figure 1, P<.0001). The unadjusted
HR was 1.65 (95% confidence interval [CI], 1.33–2.04).
The AF ablated group had better survival than the AF un-
treated group (HR, 0.39; 95% CI, 0.27–0.55) and similar
survival to the no AF group (HR, 1.15; 95% CI, 0.88–
1.51) (Figure 2).
There was no difference in mortality between the
matched AF ablated and no AF groups (P ¼ .22,
Figure 3). Both groups illustrated similar patient survival
at 1, 3, and 5 years (95% vs 94%, 90% vs 87%, and
87% vs 82% for AF ablated vs no AF, respectively). Addi-
tional comparisons were performed between matched pa-
tients undergoing isolated aortic valve replacement, mitral
valve replacement, and CABGþvalve. There was no differ-
ence in survival between patients in the AF ablated group
and patients in the no AF group undergoing any of these
procedures.
Follow-up at 1 year was available for 336 patients in the
AF ablated group. A total of 225 of these patients (67%)
had no episode of AF lasting more than 30 seconds within
the first year and were free of AAmedications and classified
as having ‘‘successful treatment.’’ Freedom fromAFandAA
medications at 1 year independently predicted long-term
survival compared with patients in whom ablation failed1344 The Journal of Thoracic and Cardiovascular Sur(unadjusted P ¼ .0003 and adjusted P ¼ .03) (Figure 4).
At last follow-up, 78% of patients were free of AF. There
was a trend for improved survival in this group (P ¼ .06)
compared with treated patients who remained in AF.
After 1 year, survivors who were successfully treated
were similar inmanyways to those patients whose treatment
failed (Table 3). However, they were younger, had lower se-
rum creatinine, andweremore likely to have no prior cardiac
operation. Seventy-seven patients who were successfully
treated after 1 year were matched with 77 patients who
had failed treatment (in AF or taking AA medication). Sur-
vival was different between these groups (Figure 5) and fa-
vored those patients who were successfully treated.
DISCUSSION
The published literature suggests that patients with AF
undergoing cardiac surgery have reduced survival com-
pared with patients in sinus rhythm.5-9 Our article
demonstrates that when select patients are treated for AF
at the time of cardiac surgery, their midterm survival is
the same as those without a history of AF. Further,
successful restoration of sinus rhythm improves survival
compared with treated patients who remain in AF,
a finding analogous to the Atrial Fibrillation Follow-Up In-
vestigation of RhythmManagement trial.4 This finding per-
sists even with the passage of time and the change of the
patient population.18
Patients undergoing cardiac surgery represent a unique
population. Adding a concomitant AF procedure does not
add much to the operation but results in sinus restoration ap-
proximately 80% of the time13,19-23 (in our study 78%,
including 67% free of AA medications and AF). At least
6 randomized trials in patients undergoing mitral valve
surgery have shown that treating AF is more likely to
restore sinus rhythm than nontreatment.14,24-29 However,gery c June 2012
TABLE 2. Comparison of characteristics of AF ablated versus no AF populations: Total sample and propensity-matched groups
Variables
Total sample (N ¼ 3014) Propensity-matched sample (N ¼ 744)
AF ablated (N ¼ 565) No AF (N ¼ 2449)
P value
AF ablated (N ¼ 372) No AF (N ¼ 372)
P valuen % n % n % n %
Demographics
Age (mean  SD) 65.9  12.2 61.7  13.8 <.0001 64.8  12.5 64.7  13.1 .9088
Male 329 58.2 1644 67.1 <.0001 224 60.2 231 62.1 .5985
Race <.0001 .8932
White 435 77.0 1718 70.2 279 75.0 282 75.8
AA 26 4.6 235 9.6 23 6.2 28 7.5
Hispanic 10 1.8 104 4.3 7 1.9 6 1.6
Asian 11 2.0 63 2.6 8 2.2 6 1.6
Other 83 14.7 329 13.4 55 14.8 50 13.4
Health characteristics
CHADS2 (mean  SD) 1.6  1.2 1.4  1.2 .0357 1.5  1.2 1.5  1.2 .8519
BMI (mean  SD) 27.5  5.9 28.0  5.8 .0751 27.5  6.0 27.8  6.0 .4750
Smoker 149 26.4 764 31.2 .0245 95 25.5 114 30.7 .1212
Diabetes 77 13.6 515 21.0 <.0001 56 15.1 61 16.4 .6146
Hypertension 321 56.8 1554 63.5 .0033 223 60.0 223 60.0 1.0000
CHF 206 36.5 580 23.7 <.0001 120 32.3 129 34.7 .4844
NYHA <.0001 .8771
Class 1 121 21.4 675 27.6 89 23.9 84 22.6
Class 2 246 43.5 928 37.9 163 43.8 159 42.7
Class 3 173 30.6 640 26.1 105 28.2 115 30.9
Class 4 25 4.4 205 8.4 15 4.0 14 3.8
Renal failure 24 4.2 119 4.9 .5366 11 3.0 14 3.8 .5416
Previous dialysis 5 0.9 61 2.5 .0187 3 0.8 3 0.8 1.0000
COPD 71 12.6 255 10.4 .1373 44 11.8 49 13.2 .5794
PVD 26 4.6 213 8.7 .0017 17 4.6 23 6.2 .3294
Moderate pulmonary HTN 188 33.3 491 20.0 <.0001 112 30.1 115 30.9 .8112
Severe pulmonary HTN 130 23.0 251 10.2 <.0001 74 19.9 75 20.2 .9270
MI 58 10.3 496 20.3 <.0001 39 10.5 50 13.4 .2140
Angina 70 12.4 824 33.6 <.0001 55 14.8 58 15.6 .7593
Stroke/TIA 57 10.1 206 8.4 .2030 32 8.6 29 7.8 .6885
Family history CAD 105 18.6 513 20.9 .2098 70 18.8 74 19.9 .7105
Surgical characteristics
No. of diseased vessels (mean  SD) 0.8  1.2 1.5  1.3 <.0001 0.9  1.2 1.0  1.2 .1065
Left main disease 30 5.4 380 15.7 <.0001 23 6.2 31 8.3 .2583
Preoperative creatinine (mean  SD) 1.17  0.8 1.19  0.9 .5784 1.13  0.7 1.13  0.5 .9887
Surgical incidence .0010 .8314
1st 465 82.3 2148 87.7 309 83.1 303 81.5
2nd 90 15.9 255 10.4 55 14.8 61 16.4
3þ 10 1.8 46 1.9 8 2.2 8 2.2
Indication of surgery <.0001 .9014
Elective 511 90.4 1889 77.1 335 90.1 337 90.6
Emergency 1 0.2 55 2.3 0 0 0 0
Urgent 53 9.4 505 20.6 37 9.9 36 9.4
Type of surgery
CABG 172 30.4 1305 53.3 <.0001 122 32.8 140 37.6 .1671
Aortic valve 167 29.6 891 36.4 .0022 128 34.4 121 32.5 .5865
Mitral valve 341 60.4 590 24.1 <.0001 201 54.0 208 55.9 .6060
Tricuspid valve 162 28.7 139 5.7 <.0001 66 17.7 63 16.9 .7714
ValveþCABG 141 25.0 423 17.3 <.0001 93 25.0 107 28.8 .2470
Previous medications
ACE 201 35.7 930 38.1 .2992 131 35.2 133 35.8 .8782
ADP 9 1.6 104 4.3 .0027 8 2.2 11 3.0 .4857
(Continued)
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Total sample (N ¼ 3014) Propensity-matched sample (N ¼ 744)
AF ablated (N ¼ 565) No AF (N ¼ 2449)
P value
AF ablated (N ¼ 372) No AF (N ¼ 372)
P valuen % n % n % n %
Aspirin 121 21.4 977 40.0 <.0001 89 23.9 100 26.9 .3542
Beta-blockers 362 64.1 1358 55.6 .0002 220 59.1 227 61.0 .6003
Warfarin 88 15.6 315 12.9 .0877 42 11.3 39 10.5 .7240
Nonstatin 28 5.0 120 4.9 .9559 15 4.0 23 6.2 .1828
Statin 240 42.5 1299 53.0 <.0001 162 43.6 175 47.0 .3383
Discharge medications
ACE 129 23.7 608 25.9 .2899 93 25.0 97 26.1 .7367
ADP 17 3.1 509 21.3 <.0001 16 4.3 22 5.9 .3177
Aspirin 500 90.1 2187 91.8 .2009 332 89.3 341 91.7 .2615
Beta-blockers 381 70.0 2063 87.0 <.0001 284 76.3 277 74.5 .5512
Warfarin 472 85.2 687 28.8 <.0001 293 78.8 300 80.7 .5234
Nonstatin 23 4.1 99 4.0 .9754 15 4.0 23 6.2 .1828
Statin 406 71.9 1854 75.7 .0571 271 72.9 282 75.8 .3559
Ambler score (mean  SD) 8.4  8.2 4.8  6.5 <.0001 6.3  6.1 6.9  8.0 .2218
AF, Atrial fibrillation; SD, standard deviation; AA, antiarrhythmic; CHADS2, Congestive heart failure, Hypertension, Age 75 years, Diabetes, previous Stroke; BMI, body mass
index; CHF, congestive heart failure; NYHA,NewYork Heart Association; COPD, chronic obstructive pulmonary disease; PVD, peripheral vascular disease;HTN, hypertension;
MI, myocardial infarction; TIA, transient ischemic attack; CAD, coronary artery disease; CABG, coronary artery bypass grafting; ACE, angiotensin-converting enzyme; ADP,
adenosine diphosphate.
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Dnone of these trials were powered or followed to look at
whether sinus restoration improved survival or reduced
other morbidity.
Few studies have attempted to establish an improved sur-
vival after the surgical treatment of AF. In a series of 103
patients with persistent AF, Louagie and colleagues30 dem-
onstrated an improved survival at 5 years in 37 patients who
underwent a Maze procedure compared with controls. They
postulated that sinus restoration (90% in Maze group vs
33% in control) explained the difference.30 However, in
the non-ablated control group, exclusion of the left atrial ap-
pendage was associated with lower mortality, suggesting
that a reduction in late stroke may play a role in both pop-
ulations. In a large series of 521 combined mitral and maze
cases, Itoh and colleagues31 demonstrated that successfulFIGURE 1. Patient survival: history of AF vs no AF. Kaplan–Meier anal-
yses of survival in AF (N¼ 813) and no AF (N¼ 2449) groups. AF, Atrial
fibrillation.
1346 The Journal of Thoracic and Cardiovascular Sursinus restoration improved survival and freedom from
stroke. However, these studies preceded current follow-up
guidelines and definitions of success. In addition, the use
of AA therapy was not considered a failure.
Our propensity-matched analysis demonstrates that in the
matched treated population, survival was the same as for pa-
tients without a history of AF. Although this could be due to
selection bias, it is important to note that thosewith success-
ful sinus restoration did have improved survival compared
with those who failed treatment. The elimination of the
left atrial appendage also may be a factor. The role of
both these factors on late stroke and survival merits future
investigation.
In North America, only 38% of patients with a history of
AF receive an AF correction procedure.10,32 For some time,FIGURE 2. Patient survival: no AF vs AF ablated vs AF untreated. Ka-
plan–Meier analyses of survival for AF ablated (N ¼ 565), AF untreated
(N ¼ 248), and no AF (N ¼ 2449) groups. AF, Atrial fibrillation.
gery c June 2012
FIGURE 3. Propensity-matched patient survival: AF ablated vs no AF. Kaplan–Meier analyses of survival for propensity-matched AF ablated (N ¼ 372)
and no AF (N ¼ 372) groups. AF, Atrial fibrillation.
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Dwe have thought that if AF can be eliminated at the time of
cardiac surgery, survival should improve to that of
patients without a history of AF.5 Our study is the first
propensity-matched analysis to demonstrate that survival
in a population in whom AF was surgically treated in accor-
dance with the Heart Rhythm Society guidelines is compa-
rable to that of patients without AF. Because successful
sinus restoration seems to have an impact, an effort should
be made to optimize success at the time of surgery. This
may have future implications on lesion set selection.FIGURE 4. Survival in AF ablated group: ‘‘success’’ (freedom from AF and A
patients in AF ablated group who had no episode of AF lasting more than 30 sec
and had AF within 1 year or were taking AA medications (failure, N ¼ 111). H
The Journal of Thoracic and CarLimitations
There are several limitations to our study that restrict our
ability to definitively state that AF treatment improved sur-
vival. The patient sample may not be adequate. Further, al-
though the patients were matched with accepted statistical
methodology, there may still be inherent differences in the
population that cannot be equated. Despite our best efforts,
we may have ‘‘selected out’’ the healthy patients who were
destined to have comparable survival. In addition, because
of the relatively small sample, we do not know the effectA therapy at 1 year) vs ‘‘failure.’’ Kaplan–Meier analyses of survival for
onds within the first year, were free of AA medications (success, N¼ 225),
R, Hazard ratio.
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TABLE 3. Comparision of characteristics of successful versus unsuccessful AF treatment patients: Total sample and propensity-matched sample 1
year after treatment
Variables
Total sample Propensity-matched sample
Success (N ¼ 203) Failure (N ¼ 104)
P value
Success (N ¼ 77) Failure (N ¼ 77)
P valuen % n % n % n %
Demographics
Age (mean  SD) 64.4  11.8 68.9  11.8 .0017 67.9  10.9 67.6  12.0 .8498
Male 118 58.1 53 51.0 .2315 42 54.5 44 57.1 .7455
Race .6895 1.0000
White 157 77.3 87 83.7 62 80.5 62 80.5
AA 10 4.9 4 3.8 3 3.9 3 3.9
Hispanic 3 1.5 2 1.9 2 1.3 2 1.3
Asian 2 1.0 1 1.0 1 2.2 1 2.2
Other 31 15.3 10 9.6 9 11.7 9 11.7
Health characteristics
CHADS2 (mean  SD) 1.4  1.2 1.7  1.2 .0115 1.5  1.2 1.5  1.1 .8869
BMI (mean  SD) 27.7  6.3 27.2  5.7 .4909 27.9  4.0 27.4  5.6 .5627
Smoker 61 30.0 30 28.8 .8271 27 35.1 24 31.2 .6075
Diabetes 24 11.8 17 16.3 .2701 9 11.7 10 13.0 .8064
Hypertension 114 56.2 56 53.8 .6998 43 55.8 40 51.9 .6277
CHF 60 29.6 42 40.4 .0566 24 31.2 27 35.1 .6075
NYHA .3968 .9619
Class 1 39 19.2 18 17.3 12 15.6 14 18.2
Class 2 105 43.5 48 37.9 41 53.3 38 49.3
Class 3 55 30.6 33 26.1 22 28.6 23 29.9
Class 4 4 4.4 5 8.4 2 2.6 2 2.6
Renal failure 3 1.5 5 4.8 .0830 2 2.6 2 2.6 1.0000
Previous dialysis 0 0.0 1 1.0 .1617 0 0.0 0 0.0 1.0000
COPD 21 10.3 12 11.5 .7493 8 10.4 8 10.4 1.0000
PVD 10 4.9 4 3.8 .6677 2 2.6 2 2.6 1.0000
Moderate pulmonary HTN 71 35.0 37 35.6 .9168 28 36.4 26 33.8 .7356
Severe pulmonary HTN 46 22.7 27 26.0 .5202 18 23.4 17 22.1 .8475
MI 12 5.9 11 10.6 .1417 4 5.2 6 7.8 .5131
Angina 19 9.4 11 10.6 .7339 7 9.1 9 11.7 .5974
Stroke/TIA 16 7.9 11 10.6 .4300 9 11.7 7 9.1 .5974
Family history CAD 38 18.7 20 19.2 .9137 13 16.9 14 18.2 .8322
Surgical characteristics
No. of diseased vessels (mean  SD) 0.6  1.0 0.8  1.1 .2829 0.7  1.1 0.7  1.1 .9018
Left main disease 8 4.0 3 2.9 .6426 1 1.3 3 3.9 .3109
Preoperative creatinine (mean  SD) 1.1  0.3 1.3  1.1 .0244 1.17  0.4 1.16  0.6 .9887
Surgical incidence .0054 .5594
1st 175 86.2 77 74.0 64 83.1 63 81.8
2nd 27 13.3 22 21.2 12 15.6 14 18.2
3þ 1 0.5 5 4.8 1 1.3 0 0.0
Indication of surgery .2816 .9999
Elective 189 93.1 100 96.2 75 97.0 74 96.1
Emergency 0 0.0 0 0.0 0 0.0 0 0.0
Urgent 14 6.9 4 3.8 2 2.6 3 3.9
Type of surgery
CABG 53 26.1 32 30.8 .3877 29 37.7 23 29.9 .3066
Aortic valve 52 25.6 26 25.0 .9066 21 27.3 18 23.4 .5783
Mitral valve 123 60.6 76 73.1 .0301 53 68.8 53 68.8 1.0000
Tricuspid valve 54 26.6 41 39.4 .0214 27 35.1 26 33.8 .8653
ValveþCABG 44 21.7 27 26.0 .3992 26 33.8 19 24.7 .2149
Previous medications
ACE 71 35.1 42 40.8 .3358 34 44.2 33 42.9 .8709
ADP 1 0.5 2 1.9 .2241 1 1.3 0 0.0 .3157
(Continued)
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Total sample Propensity-matched sample
Success (N ¼ 203) Failure (N ¼ 104)
P value
Success (N ¼ 77) Failure (N ¼ 77)
P valuen % n % n % n %
Aspirin 39 19.2 17 16.3 .5383 13 16.9 11 14.3 .6568
Beta-blockers 130 64.0 59 56.7 .2128 42 54.5 43 55.8 .8713
Warfarin 24 11.8 12 11.5 .9416 7 9.1 8 10.4 .7858
Nonstatin 12 5.9 6 5.8 .9600 4 5.2 4 5.2 1.0000
Statin 78 38.4 45 43.3 .4122 31 40.3 33 42.9 .7437
Discharge medications
ACE 49 24.4 26 25.2 .8685 24 31.2 19 24.7 .3691
ADP 5 2.5 0 0.0 .1074 0 0.0 0 0.0 1.0000
Aspirin 185 91.1 99 95.2 .2010 66 85.7 72 93.5 .5131
Beta-blockers 133 66.8 70 69.3 .6652 51 66.2 52 67.5 .8641
Warfarin 176 87.1 91 87.5 .9265 67 87.0 69 89.6 .6159
Nonstatin 12 5.9 3 2.9 .2443 1 1.3 2 2.6 .5599
Statin 147 72.4 76 73.1 .9018 51 66.2 56 72.7 .3816
Ambler score (mean  SD) 7.0  7.3 10.3  8.3 .0004 7.8  8.7 7.9  6.3 .8819
SD, Standard deviation; AA, antiarrhythmic; CHADS2, Congestive heart failure, Hypertension, Age 75 years, Diabetes, previous Stroke; BMI, body mass index; CHF, conges-
tive heart failure; NYHA, New York Heart Association; COPD, chronic obstructive pulmonary disease; PVD, peripheral vascular disease; HTN, hypertension; MI, myocardial
infarction; TIA, transient ischemic attack; CAD, coronary artery disease; CABG, coronary artery bypass grafting; ACE, angiotensin-converting enzyme; ADP, adenosine diphos-
phate.
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Dof nontreatment in this group; however, we do know that pa-
tients had a worse survival when treatment failed. AF abla-
tion was not performed on these patients when the surgeon
judged the procedure too complex or the patients were too
ill and the risk outweighed the potential benefit; generally,
these patients were likely to haveworse survival. Thus, little
information can be gained from the untreated population in
this study. Because the untreated patients were different
from the treated patients, we did not find an adequate sam-
ple for matching this group. Other limitations include a lack
of knowledge of late causes of death that may be unrelatedFIGURE 5. Survival after 1 year in propensity-matched patients: ‘‘success’’ (fre
of survival after 1 year in propensity-matched patients; a comparison of AF tre
The Journal of Thoracic and Carto AF. Late adverse events were not investigated; only mid-
term survival was investigated. Longer follow-up will pro-
vide a more definitive answer.
CONCLUSIONS
In matched patients with a history of AF who underwent
ablation during concomitant surgery, there was no differ-
ence in early or midterm survival compared with patients
without a preoperative history of AF. The 67% of patients
who were free of AA therapy and AF at 1 year had better
long-term survival, and 78% of patients in sinus rhythmedom fromAF and AA therapy at 1 year) vs failure. Kaplan–Meier analysis
atment success (N ¼ 77) and failure (N ¼ 77) groups.
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Dat last follow-up showed a trend (P¼ .06) toward improved
survival compared with patients in AF. In matched patients,
successful treatment predicted survival, even after 1 year.
Because several prior studies have indicated reduced sur-
vival in patients with a history of AF, these results are en-
couraging and merit further investigation. This may have
implications for a broader application of AF surgery in
low-risk patients.References
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Dr John Doty (Murray, Utah). This study emphasizes the im-
portance of concomitant treatment of AF, particularly your last
graphs. Your follow-up is relatively short, but we may see that
those patients have improved survival by treatment of AF. There
is ongoing debate about the wide range of operations that are
used for the treatment of AF. Would you describe the particular
procedures your group uses for treatment of AF and how you de-
cide which patient gets what procedure in this complex group?
Dr Lee. I have another article that I am putting together that
looks at AF by lesion set, and in general our results are approxi-
mately 75% to 90% depending on the type of procedure that we
use in the patient population. Our rule of thumb is essentially
this. The American College of Cardiology/American Heart Asso-
ciation recommends treating everybody with AF if it does not add
anything more to the procedure. So if you are performing mitral
valve surgery, you are fairly obligated to do a full left-sided
Maze and strongly consider a right side, especially as more data
emerge that doing both by atrial lesion sets may improve AF out-
comes. On the flip side, if you have an elderly person undergoing
CABG, especially off-pump, and you are not going to open the
heart, well, it may be reasonable to do pulmonary vein isolationgery c June 2012
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Dalone. We segment it by procedure and by how AF affects the pa-
tient. If AF is a real problem, we make every effort to treat it with
the biatrial lesion set. If it is paroxysmal, especially if we are not
going to open the heart anyway, wewould do a more limited lesion
set like a PVI alone. And for those patients in between those ex-
tremes, we perhaps do a left-sided only Maze.
Dr Doty.Maybe you could clarify a bit more. When you say le-
sion sets, what energy modality are you using? You did mention in
your article sometimes you have cut and sew as an option.
Dr Lee. In the article you wrote 2 years ago, you showed that
cut and sew is probably better than everything else, and even
though some of the other reports conflict with that, we have a sim-
ilar experience. Now if you have a patient with AF and that is the
number 1 problem, you are going to do a cut-and-sewMaze. If you
have a patient who has paroxysmal or perhaps long-standing per-
sistent and not permanent AF, you will perform bipolar RF. The
majority of our patients are older, more frail, and so approximately
75% of our patients receive bipolar radiofrequency with supple-
mentation at the annulus with cryothermia.
Dr Doty.We all recognize that some surgeons may not be will-
ing to add an additional procedure for AF to what they are doing,
particularly if it is complex. Can you estimate for us howmuch ad-
ditional time it takes your group to do some type of ablative or inci-
sional Maze procedure?
Dr Lee. That is important, but even the experience of our group
is not as important as the experience of the whole population.
Gammie and colleagues wrote an article using the Society of Tho-
racic Surgeons’ database. In that added meta-analysis, they
showed that it added 9minutes to crossclamp time and 9 additional
minutes to bypass time in general. With the bypass time, you are
clamping the beating heart anyway. I think it is even less than
that in many instances, so if we are using bipolar radiofrequency
we go on pump. We do the pulmonary vein isolations on pump.
We stop the heart. We do the connecting lesions, and that really
does not take more than 1 minute of clamp time. Then we unclamp
and do the right-sided lesions if we are going to do it, and again
even if you do multiple lesions it is 40 seconds per burn times 3.
It is just a couple minutes per lesion, so in all it adds approximately
18 minutes at the most, but in general, more like 10 minutes for us.
Dr Doty. Your group is similar to ours. We have a strong bias to
treat everyone who presents with AF with some type of procedure
during their concomitant operation. I am particularly interested in
the subset of patients who had existing AF but did not receive
a concomitant procedure. You noted these patients were more ill
and had more comorbidities. If that is the case, shouldn’t these pa-
tients be the very ones who receive a concomitant operation, and, if
not, can you explain which patients in whom you would not per-
form an AF operation?The Journal of Thoracic and CarDr Lee. I did not analyze those data, but you know we have
shifted. Now we look at how many patients we have with AF,
and now we are at 90% of patients treated for AF, so we have
had a paradigm shift. We have a group we assembled right around
the beginning of that time period, and as we have gone on we have
increased the application, but we also use alternate energy sources,
so if you have a redo, for example, say a redo mitral that is pretty
stuck, you don‘t want to dissect out the whole heart. I don’t want to
do a cut-and-sew Maze in that patient. I don‘t even want to do bi-
polar radiofrequency in that patient because I don’t want to get
around the left-sided veins. But what we will do is use a CryoCath
(Medtronic Corporation, Minneapolis, Minn) around the entire
surface or Frigitronics cryo (Atricure Corporation, Cincinnati,
Ohio), 1 of those 2, and I would say we are down to not operating
on approximately 10% of the patients. In general, if we are not go-
ing to open the heart, say it is an 85-year-old patient with a redo
aortic valve, we are probably just going to do the redo aortic valve.
If it is a CABG, especially a redo, we probably would let that go if
it is an older or frail patient. That being said, now we are down to
approximately 10% or less of patients with a history of AF who are
in that category.
Dr Doty. Let me clarify. Are there specific patients in
whom you would not perform a concomitant operation? You
mentioned redos, if they are older. Are there other criteria you gen-
erally use?
Dr Lee. If the patient is older, we are not going to open the
heart. Even if the patient is old and a redo and we are going to per-
formmitral valve surgery, that is still easy to do a left sided, but the
guidelines state that it adds to the operation significantly, so I
would not open the heart in a 90-year-old patient with redo aortic
valves and patent grafts. That is clearly a patient I would not oper-
ate on. I cannot give you an individual patient because it is a case-
by-case decision, but that is clearly to the extreme where I say no.
Dr William Northrup (Atlanta, Ga). I wonder if the phrase
‘‘expected survival’’ is a little misleading. For instance, when we
say that mitral valve repair has the potential to restore expected
survival, we are comparing it with a normal matched population.
In this case, you are comparing 2 surgical subgroups. When I first
read the article, I thought this is pretty exciting. Nevertheless, the
article presents exciting data.
Dr Lee. Thank you for your comment, and wewill take that into
consideration for the final article. We did not compare with the
general population because we do not know what that survival
should be compared with regular cardiac surgery, but we do
know what survival should be for similar patients undergoing aor-
tic valve surgery, mitral valve surgery, and CABG, so by the word
‘‘expected,’’ that is what we meant, and we did restore it to that
population.diovascular Surgery c Volume 143, Number 6 1351
